Halbert Hargrove Global Advisors, LLC Denali Therapeutics Inc. Transaction History
Halbert Hargrove Global Advisors, LLC
- $2.02 Billion
- Q3 2025
A detailed history of Halbert Hargrove Global Advisors, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Halbert Hargrove Global Advisors, LLC holds 104 shares of DNLI stock, worth $1,794. This represents 0.0% of its overall portfolio holdings.
Number of Shares
104Holding current value
$1,794% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
249Shares Held
135MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$227 Million0.01% of portfolio
-
Baillie Gifford & CO12MShares$206 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$204 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$114 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$108 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.31B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...